Shares of Equillium, Inc. (EQ) are gaining more than 14 percent or $0.86 in Friday's morning trade at $6.86.
Thursday, Equillium said it has received FDA clearance to commence a phase III clinical trial of Itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome or ARDS. The company plans to begin patient enrollment in the trial named EQUINOX in the fourth quarter, with initial clinical data expected mid-year 2021.
Equillium has traded in a range of $2.20 to $27.05 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.